Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 42 citing articles:

Antibodies to watch in 2024
Silvia Crescioli, Hélène Kaplon, Alicia M. Chenoweth, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 84
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo, et al.
JAMA (2024) Vol. 332, Iss. 7, pp. 561-561
Open Access | Times Cited: 37
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 35
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 468-482
Closed Access | Times Cited: 30
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Weishi Cheng, Kai Kang, Ailin Zhao, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 25
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Sophia Frentzas, Anna Rachelle Mislang, Charlotte Lemech, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 4, pp. e008037-e008037
Open Access | Times Cited: 14
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 11
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 9
Overcoming immune evasion with innovative multi-target approaches for glioblastoma
Hai Su, Peng Yin, Yi‐Long Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Zhengdong Ai, Bing Wang, Yunlong Song, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
Lei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 3, pp. 465-475
Open Access | Times Cited: 22
Ivonescimab: First Approval
Sohita Dhillon
Drugs (2024) Vol. 84, Iss. 9, pp. 1135-1142
Closed Access | Times Cited: 7
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Yi Zhao, Ying He, Wei Wang, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 10, pp. 1347-1356
Closed Access | Times Cited: 5
Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review
Alzahra'a Al matairi, Bara M Hammadeh, Abdullah Yousef Aldalati, et al.
Cureus (2025)
Open Access
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer
Sophia Daum, Lilith Decristoforo, Mira Mousa, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors
Feng‐Hua Wang, Xiaoli Wei, Yulong Zheng, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment
Saqib Raza Khan, Daniel Breadner
Current Oncology (2025) Vol. 32, Iss. 4, pp. 206-206
Open Access
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
Dongliang Bian, Shuyu Ji, Yue Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Lorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
PD-1/PD-L1 inhibitors combined with anti-angiogenic drugs for advanced triple-negative breast cancer: synergistic mechanisms and research progress
Rui Xu, Shaowei Guo, Qingle Song, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 211, pp. 104740-104740
Closed Access
Page 1 - Next Page

Scroll to top